Last reviewed · How we verify
Hydronidone capsules
Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.
Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown).
At a glance
| Generic name | Hydronidone capsules |
|---|---|
| Also known as | F351 |
| Sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology/Inflammation |
| Phase | Phase 3 |
Mechanism of action
As a synthetic corticosteroid, hydronidone exerts anti-inflammatory effects through glucocorticoid receptor activation, leading to decreased production of inflammatory cytokines and immune cell activation. It is used in capsule formulation for systemic delivery to treat inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown)
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression/increased infection risk
- Adrenal suppression
Key clinical trials
- A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis (PHASE2)
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. (PHASE3)
- Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls (PHASE1)
- A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis (PHASE2)
- A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis (PHASE3)
- A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency (PHASE1)
- Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide (PHASE1)
- QTc Assessment in a Single-Dose Study of Hydronidone Capsules (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydronidone capsules CI brief — competitive landscape report
- Hydronidone capsules updates RSS · CI watch RSS
- Beijing Continent Pharmaceutical Co, Ltd. portfolio CI